(:APTX)

Mar 30, 2023 04:05 pm ET
Aptinyx Reports on Fourth Quarter and Full Year 2022 Results and Highlights and Review of Strategic Alternatives
Aptinyx Inc. (Nasdaq: APTX) today reported recent business updates and financial results for the fourth quarter and full year 2022.
Feb 27, 2023 04:03 pm ET
Aptinyx Reports Results from Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies and Provides Pipeline and Corporate Update
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced results from a Phase 2 clinical study evaluating the effects of NYX-458 in patients with cognitive impairment associated with Parkinson’s disease and dementia with Lewy bodies. Across the overall study population, NYX-458 did not demonstrate clinically meaningful improvements over placebo on the study’s efficacy endpoints. The results do not support further development of NYX-458 by the company.
Jan 31, 2023 07:47 am ET
Aptinyx to Present at the SVB Securities Global Biopharma Conference
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Andy Kidd, M.D., president & chief executive officer, will participate in a virtual fireside chat at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 10:00 a.m. ET.
Nov 10, 2022 07:45 am ET
Preclinical Data from Aptinyx’s NMDA Receptor Modulators to be Presented at the 52nd Annual Meeting of the Society for Neuroscience
Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced upcoming poster presentations at the 52nd Annual Meeting of the Society for Neuroscience being held November 12-16, 2022 in San Diego, CA. The presentations include preclinical data supporting the development of NYX-783, an NMDA receptor positive allosteric modulator in post-traumatic stress disorder and opioid use disorder.
Nov 08, 2022 04:05 pm ET
Aptinyx Reports Third Quarter 2022 Financial Results and Recent Highlights
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the third quarter of 2022 and provided key business updates across the company’s clinical-stage pipeline of novel NMDA receptor modulators.
Nov 03, 2022 07:30 am ET
Clinical Evaluation of Aptinyx's NYX-783 for Treatment of Opioid Use Disorder to Be Funded by $5.6 Million NIH Grant
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced the finalization of a $5.6 million grant under the National Institutes of Health (NIH) Helping to End Addiction Long-term (HEAL) Initiative, supporting the development of NYX-783 for the treatment of opioid use disorder (OUD). NYX-783 is an NMDA receptor positive allosteric modulator also in Phase 2b development by Aptinyx for the treatment of post-traumatic stress disorder (PTSD).
Oct 18, 2022 07:45 am ET
Aptinyx to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, November 8, 2022 at 5:00 p.m. ET to report third quarter 2022 financial results and discuss recent business highlights.
Aug 25, 2022 07:30 am ET
Aptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson’s Disease and Dementia with Lewy Bodies
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the completion of enrollment of 99 patients in the company’s ongoing Phase 2 study of NYX-458 in cognitive impairment associated with Parkinson’s disease and dementia with Lewy bodies. Patients recently enrolled in the study are completing the 12-week treatment period and 30-day safety follow-up period. The company expects to report results from the study in 1Q 2023.
Aug 12, 2022 07:15 am ET
Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Fibromyalgia
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced results from a Phase 2b clinical study evaluating the effects of NYX-2925 in patients with fibromyalgia. NYX-2925 did not achieve statistically significant separation from placebo on the study’s primary endpoint, which assessed the change from baseline in average daily pain on the numeric rating scale (NRS) during week 12.
Aug 04, 2022 04:05 pm ET
Aptinyx Reports Second Quarter 2022 Financial Results and Recent Highlights
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the second quarter of 2022 and provided key business updates across the company’s clinical-stage pipeline of novel NMDA receptor modulators.
Jul 15, 2022 07:47 am ET
Aptinyx to Report Second Quarter 2022 Financial Results on Thursday, August 4, 2022
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, August 4, 2022 at 5:00 p.m. ET to report second quarter 2022 financial results and discuss recent business highlights.
Jun 22, 2022 07:47 am ET
Aptinyx to Participate in H.C. Wainwright 1st Annual Mental Health Conference
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that company management will present at the H.C. Wainwright 1st Annual Mental Health Conference. The conference is being held at the Lotte New York Palace Hotel and virtually from June 27–28, 2022.
May 18, 2022 07:37 am ET
Aptinyx to Participate in H.C. Wainwright Global Investment Conference
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that company management will present at the H.C. Wainwright Global Investment Conference to be held May 23-26, 2022. The presentation will be available on-demand through the H.C. Wainwright conference portal, beginning at 7:00 AM ET on Tuesday, May 24, 2022.
May 17, 2022 07:37 am ET
Aptinyx Announces Poster Presentation Highlighting Preclinical Data on NYX-783 in Models of PTSD at the 2022 American Psychiatric Association Annual Meeting
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that data from preclinical studies of NYX-783 in models of post-traumatic stress disorder (PTSD) will be presented in a poster at the American Psychiatric Association Annual Meeting being held May 21 – 25, 2022 in New Orleans, LA.
May 12, 2022 04:05 pm ET
Aptinyx Reports First Quarter 2022 Financial Results and Highlights Recent Clinical Progress
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today reported financial results for the first quarter of 2022 and highlighted recent progress across the company’s pipeline of novel, clinical-stage, NMDA receptor modulators.
Apr 29, 2022 07:37 am ET
Aptinyx Presents Preclinical Data on NYX-783 in Models of PTSD at 2022 Society of Biological Psychiatry Annual Meeting
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today presented data from preclinical studies of NYX-783 in models of post-traumatic stress disorder (PTSD) at the Society of Biological Psychiatry (SOBP) Annual Meeting, being held April 28 – April 30, 2022 in New Orleans, Louisiana. The company is participating in a symposium discussing the role of NMDA receptor function in relation to prefrontal cortex activity in PTSD.
Apr 27, 2022 07:47 am ET
Aptinyx to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, May 12, 2022 at 5:00 p.m. ET to report first quarter 2022 financial results and discuss recent business highlights.
Apr 20, 2022 07:47 am ET
Aptinyx Announces Publication in Molecular Psychiatry Demonstrating Reduction of Spontaneous Recovery of Fear with NYX-783
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that data from preclinical studies evaluating NYX-783, a novel NMDA receptor positive allosteric modulator, in models of post-traumatic stress disorder (PTSD) were published in the journal, Molecular Psychiatry.
Apr 07, 2022 07:00 am ET
Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced results from a Phase 2b clinical study evaluating the effects of NYX-2925 in patients with painful diabetic peripheral neuropathy (DPN). NYX-2925 did not achieve statistically significant separation from placebo on the study’s primary endpoint, which assessed the change from baseline in average daily pain on the numeric rating scale (NRS) during week 12.
Mar 23, 2022 04:05 pm ET
Aptinyx Reports Fourth Quarter and Full Year 2021 Results and Highlights
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the fourth quarter and full year 2021 and provided updates across the company’s pipeline of novel NMDA receptor modulators.
Mar 09, 2022 07:47 am ET
Aptinyx to Report Fourth Quarter and Full Year 2021 Financial Results on Wednesday, March 23, 2022
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Wednesday, March 23, 2022 at 5:00 p.m. ET to report fourth quarter and full year 2021 financial results and discuss recent business highlights.
Mar 01, 2022 07:47 am ET
Aptinyx to Participate in the 42nd Annual Cowen Health Care Conference
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Andy Kidd, M.D., president & chief executive officer, will participate in the Neuropsychiatry Panel discussion at the 42nd Annual Cowen Health Care Conference at 9:10 a.m. EST on Monday, March 7, 2022.
Feb 28, 2022 07:25 am ET
Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Fibromyalgia
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the completion of enrollment of 305 patients in the company’s ongoing Phase 2b study of NYX-2925 in fibromyalgia. Patients recently enrolled in the study are completing the 12-week treatment period and 30-day safety follow-up period. The company expects to report results from the study in early to mid 3Q 2022.
Feb 09, 2022 08:47 am ET
Aptinyx Hosts Virtual Portfolio Review Event to Showcase NYX-2925 in Chronic Pain and Provide Update on Clinical Development Programs
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, will host a virtual portfolio review event today beginning at 10:00 a.m. ET. Presented in a live webcast format, the company will discuss its approach to the development of novel NMDA receptor modulators and review its pipeline of four clinical development programs, with particular focus on NYX-2925 in chronic pain.
Feb 09, 2022 08:00 am ET
Aptinyx Hosts Virtual Portfolio Review Event to Showcase NYX-2925 in Chronic Pain and Provide Update on Clinical Development Programs
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, will host a virtual portfolio review event today beginning at 10:00 a.m. ET. Presented in a live webcast format, the company will discuss its approach to the development of novel NMDA receptor modulators and review its pipeline of four clinical development programs, with particular focus on NYX-2925 in chronic pain.
Feb 09, 2022 07:00 am ET
Aptinyx Hosts Virtual Portfolio Review Event to Showcase NYX-2925 in Chronic Pain and Provide Update on Clinical Development Programs
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, will host a virtual portfolio review event today beginning at 10:00 a.m. ET. Presented in a live webcast format, the company will discuss its approach to the development of novel NMDA receptor modulators and review its pipeline of four clinical development programs, with particular focus on NYX-2925 in chronic pain.
Feb 08, 2022 07:37 am ET
Aptinyx to Present at the SVB Leerink 11th Annual Global Healthcare Conference
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Andy Kidd, M.D., president & chief executive officer, will participate in a virtual fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on Thursday, February 17, 2022 at 10:40 a.m. ET.
Feb 03, 2022 07:37 am ET
Aptinyx Announces Formation of Scientific Advisory Board
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the formation of its Scientific Advisory Board (SAB), comprising leading researchers and physicians in the areas of neuropsychiatry, neurology, and chronic pain. The SAB will work closely with the Aptinyx management team to provide scientific and clinical input into the investigation, characterization, and therapeutic application of the novel NMDA receptor modulation mechanism underpinning the company’s platf
Jan 06, 2022 07:37 am ET
Aptinyx Highlights Key Goals and Anticipated Development Milestones for 2022
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today provided a corporate update and highlighted development milestones anticipated in 2022.
Dec 20, 2021 07:47 am ET
Aptinyx to Host Virtual Portfolio Review Event on February 9th, 2022
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it will host a virtual portfolio review event on Wednesday, February 9, 2022 from 10:00 a.m. to 11:30 a.m. ET. The live webcast event will review Aptinyx’s full pipeline of clinical development programs, with particular focus on NYX-2925, the company’s drug candidate in development for the treatment of chronic pain.
Dec 16, 2021 07:37 am ET
Aptinyx Initiates Phase 2b Study of NYX-783 in Patients with Post-Traumatic Stress Disorder
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the initiation of a Phase 2b study evaluating 50 mg QD of NYX-783 in 300 patients with post-traumatic stress disorder (PTSD). The Phase 2b study is designed to be well-positioned for consideration as registration-supportive, taking into account guidance received in a Type C meeting with the U.S. Food and Drug Administration (FDA) earlier this year. Initiation of this study follows the observation of clinically meani
Dec 13, 2021 07:49 am ET
Aptinyx to Present at the 40th Annual J.P. Morgan Healthcare Conference
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Andy Kidd, M.D., president & chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Thursday, January 13, 2022 at 12:00 p.m. Pacific Time at the Westin St. Francis Hotel in San Francisco, California.
Nov 18, 2021 07:49 am ET
Aptinyx to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference being held November 29, 2021 through December 2, 2021.
Nov 09, 2021 04:05 pm ET
Aptinyx Reports Third Quarter 2021 Financial Results and Recent Highlights
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the third quarter of 2021 and provided key business updates across the company’s clinical-stage pipeline of novel NMDA receptor modulators.
Oct 27, 2021 06:47 am ET
Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the completion of enrollment in the company’s ongoing Phase 2b study of NYX-2925 for the treatment of painful diabetic peripheral neuropathy (DPN). Patients recently enrolled in the study are completing the 12-week treatment period and 30-day safety follow-up period. The company expects to report results from the study in early to mid 2Q 2022.
Oct 25, 2021 07:32 am ET
Aptinyx to Report Third Quarter 2021 Financial Results on Tuesday, November 9, 2021
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, November 9, 2021 at 5:00 p.m. ET to report third quarter 2021 financial results and discuss recent business highlights.
Oct 20, 2021 07:57 am ET
Aptinyx Appoints Gilmore O’Neill, M.B., M.M.Sc., to Board of Directors
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced the appointment of Gilmore O’Neill, M.B., M.M.Sc., to the company’s board of directors. Dr. O’Neill currently serves as chief medical officer and executive vice president of research and development at Sarepta Therapeutics.
Sep 20, 2021 07:57 am ET
Aptinyx to Participate in 2021 Cantor Virtual Global Healthcare Conference
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., chief executive officer, will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021 at 10:00 a.m. ET.
Sep 16, 2021 06:37 am ET
Aptinyx Secures $50 Million Growth Capital Credit Facility from K2 HealthVentures
“Access to this capital provides us with additional financial resources as we advance toward three Phase 2 clinical study readouts in 2022 and initiate two additional Phase 2 studies in the coming months,” said Norbert Riedel, Ph.D., chief executive officer of Aptinyx. “We are pleased with the terms of the loan and the flexibility this facility offers to Aptinyx. The K2HV team has an excellent track record of partnering with innovative growth companies and an astute perspective on R&D value creation. We appreciate their support as we advance our pipeline.”
Aug 31, 2021 07:57 am ET
Aptinyx to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that company management will present at the H.C. Wainwright 23rd Annual Global Investment Conference to be held virtually September 13-15, 2021.
Aug 10, 2021 05:49 pm ET
Aug 10, 2021 04:10 pm ET
Aptinyx Reports Second Quarter 2021 Financial Results and Business Highlights
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today reported financial results for the second quarter of 2021 and provided key business updates.
Aug 03, 2021 07:57 am ET
Aptinyx to Participate in 2021 Wedbush PacGrow Healthcare Virtual Conference
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that Norbert Riedel, Ph.D., chief executive officer, will participate in the “Brains of the Operation - Novel Approaches in Neuro” panel discussion at the Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 10 at 12:00 p.m. ET.
Jul 26, 2021 07:57 am ET
Aptinyx to Report Second Quarter 2021 Financial Results on Tuesday, August 10, 2021
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, August 10, 2021 at 5:00 p.m. ET to report second quarter 2021 financial results and discuss recent business highlights.
Jul 12, 2021 07:57 am ET
Aptinyx to Participate in William Blair Biotech Focus Conference 2021
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that Norbert Riedel, Ph.D., chief executive officer, will participate in the Updates in Neuropysch panel discussion at the William Blair Biotech Focus Conference on Thursday, July 15 at 12:00 p.m. ET.
Jul 06, 2021 07:57 am ET
Aptinyx to Participate in Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that management will participate in a fireside chat at the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit on Tuesday, July 13 at 3:40 p.m. ET. A live webcast of the event will be available to clients of Cowen.
Jun 17, 2021 07:57 am ET
Aptinyx to Participate in Upcoming Investor Conferences
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that the Company will be participating in two upcoming investor conferences:
Jun 15, 2021 04:10 pm ET
Aptinyx Provides Update on NYX-783 Development Program for the Treatment of Post-Traumatic Stress Disorder
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that it has finalized the design of its Phase 2b program for NYX-783 in patients with post-traumatic stress disorder (PTSD) after having received the minutes from its recent Type C meeting with the U.S. Food and Drug Administration (FDA). The company expects to initiate the Phase 2b program in the fourth quarter of 2021. Aptinyx also announced that, in its preparation for Phase 2b, it identified a statistical error made by th
Jun 11, 2021 09:31 am ET
Thinking about buying stock in Vaxart, Graybug Vision, Jaguar Health, iBio, or Aptinyx?
NEW YORK, June 11, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VXRT, GRAY, JAGX, IBIO, and APTX.
May 13, 2021 04:05 pm ET
Aptinyx Reports First Quarter 2021 Financial Results and Highlights
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today reported financial results for the first quarter of 2021 and highlighted recent progress across the company’s pipeline of novel, clinical-stage, NMDA receptor modulators.
May 10, 2021 07:57 am ET
Aptinyx Appoints Joan W. Miller, M.D. to Board of Directors
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the election of Joan W. Miller, M.D., to the company’s Board of Directors. Dr. Miller currently serves as the David Glendenning Cogan Professor of Ophthalmology and Chair of the Department of Ophthalmology at Harvard Medical School, as well as Chief of Ophthalmology at both Massachusetts Eye and Ear and Massachusetts General Hospital, and Ophthalmologist-in-Chief at Brigham and Women’s Hospital.
Apr 29, 2021 04:05 pm ET
Aptinyx to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, May 13, 2021 at 5:00 p.m. ET to report first quarter 2021 financial results and discuss recent business highlights.
Apr 29, 2021 06:47 am ET
Aptinyx Presents Additional Positive Data from Phase 2 Exploratory Study of NYX-783 in PTSD at Society of Biological Psychiatry Annual Meeting
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today presented additional data from its exploratory Phase 2 study of NYX-783 in patients with post-traumatic stress disorder (PTSD) at the Society of Biological Psychiatry (SOBP) Annual Meeting being held virtually April 29 - May 1, 2021.
Apr 27, 2021 07:57 am ET
Aptinyx to Participate in Upcoming Conferences
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the Company will be participating in two upcoming conferences:
Apr 06, 2021 06:37 am ET
Aptinyx Recommences Phase 2 Study of NYX-458 in Patients with Cognitive Impairment Associated with Parkinson’s Disease Dementia and Dementia with Lewy Bodies
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it has recommenced patient screening in a Phase 2 study of NYX-458 in patients with mild cognitive impairment and mild dementia associated with Parkinson’s disease and dementia with Lewy bodies. The company anticipates reporting data from this study in the second half of 2022.
Mar 24, 2021 04:05 pm ET
Aptinyx Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the fourth quarter and full year 2020 and provided updates across the company’s pipeline of novel NMDA receptor modulators.
Mar 02, 2021 08:31 am ET
Aptinyx to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, March 24, 2021
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Wednesday, March 24, 2021 at 5:00 p.m. ET to report fourth quarter and full year 2020 financial results and discuss recent business highlights.
Feb 22, 2021 08:30 am ET
Aptinyx to Participate in Upcoming Investor Conferences
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management is scheduled to participate in two upcoming investor conferences:
Feb 11, 2021 08:30 am ET
Aptinyx to Participate at 10th Annual SVB Leerink Global Healthcare Conference
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will participate in a virtual fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 10:40 a.m. EST.
Jan 19, 2021 08:31 am ET
Aptinyx Announces Publication of Review Article Highlighting Preclinical Data in Medicine in Drug Discovery Demonstrating the Potential of NYX-2925 to Treat Chronic, Centralized Pain Conditions
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the publication of a recent review article in Medicine in Drug Discovery featuring data on its novel N
Jan 05, 2021 08:37 am ET
Aptinyx to Participate in H.C. Wainwright BioConnect 2021 Conference
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will participate in the H.C. Wainwright BioConnect 2021 Conference to be held virtually January 11-14, 2021.
Jan 04, 2021 07:57 am ET
Aptinyx Announces Recommencement of Phase 2 Study of NYX-2925 in Patients With Painful Diabetic Peripheral Neuropathy
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that in December it recommenced patient recruitment and screening in a Phase 2 study of NYX-2925 in patients with painful diabetic peripheral neuropathy (DPN). Enrollment in the study had been suspended due to the escalation of the COVID-19 pandemic in the United States.
Dec 21, 2020 08:30 am ET
Aptinyx to Present at the 39th Annual J.P. Morgan Healthcare Conference
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will present virtually at the 39th Annual J.P. Morgan Healthcare Conference. Norbert Riedel, Ph.D., chief executive officer, is scheduled to present on Thursday, January 14, 2021 at 9:10 a.m. Eastern Time.
Dec 16, 2020 08:30 am ET
Aptinyx Appoints Andy Kidd, M.D., President and Chief Operating Officer
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the appointment of Andy Kidd, the company’s current chief operating officer, to the role of president and chief operating officer, effective December 14, 2020.
Nov 12, 2020 04:03 pm ET
Aptinyx Reports Third Quarter 2020 Financial Results and Recent Highlights
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the third quarter of 2020 and highlighted recent progress across the company’s clinical-stage pipeline of novel NMDA receptor modulators.
Nov 10, 2020 08:37 am ET
Aptinyx to Participate in Upcoming Virtual Investor Conferences
EVANSTON, Ill., November 10, 2020 – Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management is scheduled to participate in two upcoming investor conferences:
Oct 29, 2020 08:37 am ET
Aptinyx to Report Third Quarter Financial Results on Thursday, November 12, 2020
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, November 12, 2020 at 5:00 p.m. ET to report third quarter 2020 financial results and discuss recent business highlights.
Oct 26, 2020 04:01 pm ET
Aptinyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the closing of its public offering of 16,100,000 shares of its common stock, which included the exercise in full of the underwriters’ option to purchase additional shares, at a public offering price of $3.00 per share. All of the shares sold in the offering were sold by Aptinyx. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Aptinyx, wer
Oct 21, 2020 10:59 pm ET
Aptinyx Announces Pricing of Public Offering of Common Stock
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the pricing of its public offering of 14,000,000 shares of its common stock at a public offering price of $3.00 per share. All of the shares sold in the offering will be sold by Aptinyx. In addition, Aptinyx has granted the underwriters a 30-day option to purchase up to 2,100,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions.
Oct 20, 2020 04:01 pm ET
Aptinyx Announces Proposed Public Offering of Common Stock
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it intends to offer and sell 12,000,000 shares of its common stock in an underwritten public offering. All of the shares sold in the offering will be sold by Aptinyx. Aptinyx also expects to grant the underwriters a 30-day option to purchase up to an additional 1,800,000 shares to be issued and sold in the public offering. The offering is subject to market and other conditions, and there can be no assurances as
Oct 20, 2020 09:31 am ET
Thinking about buying stock in Aptinyx, Acorda Therapeutics, T-Mobile, Best Buy, or Advanced Micro Devices?
NEW YORK, Oct. 20, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APTX, ACOR, TMUS, BBY, and AMD.
Oct 19, 2020 04:44 pm ET
Aptinyx Reports Positive, Statistically Significant, Top-line Data From Phase 2 Study of NYX-783 in Patients With Post-Traumatic Stress Disorder
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced positive results from the first Phase 2 study of its novel NMDA receptor modulator, NYX-783, in 153 patients with post-traumatic stress disorder (PTSD). In the Phase 2 study, NYX-783 demonstrated statistically significant and clinically meaningful efficacy results and a favorable adverse event and tolerability profile. Based on these results, the company expects to initiate a pivotal study in 2021.
Sep 28, 2020 08:27 am ET
Aptinyx Recommences Patient Recruitment in Phase 2 Study of NYX-2925 in Patients with Fibromyalgia
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it has re-activated study sites and recommenced patient recruitment in a Phase 2 study of NYX-2925 in patients with fibromyalgia. Enrollment in the study had been suspended in March 2020 due to the escalation of the COVID-19 pandemic in the United States.
Sep 03, 2020 08:37 am ET
Aptinyx to Present at Upcoming Virtual Investor Conferences
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will be presenting at the following virtual investor conferences:
Aug 13, 2020 04:05 pm ET
Aptinyx Reports Second Quarter 2020 Financial Results and Highlights
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the second quarter of 2020 and highlighted recent progress across the company’s clinical-stage pipeline of novel NMDA receptor modulators.
Aug 04, 2020 08:37 am ET
Aptinyx to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will be presenting at the 2020 Wedbush PacGrow Healthcare Virtual Conference. The presentation will take place on Tuesday, August 11, 2020 at 2:20 PM EDT.
Jul 30, 2020 04:01 pm ET
Aptinyx to Report Second Quarter Financial Results on Thursday, August 13, 2020
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, August 13, 2020 at 5:00 p.m. ET to report second quarter 2020 financial results and discuss recent business highlights.
Jul 08, 2020 08:37 am ET
Aptinyx to Host PTSD-Focused R&D Day on August 5th, 2020
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it will host a virtual R&D Day focused on the company’s development efforts in post-traumatic stress disorder (PTSD) on Wednesday, August 5, 2020, from 10:00 a.m. to 11:30 a.m. ET.
Jun 26, 2020 08:37 am ET
Aptinyx to be Added to Russell 2000® Index
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, will be added as a member of the US small-cap Russell 2000® Index. The addition will be effective after the US market opens on June 29, 2020 as part of the 2020 Russell US Indexes annual reconstitution.
Jun 18, 2020 07:57 am ET
Aptinyx Completes Enrollment in Phase 2 Exploratory Study of NYX-783 in Post-Traumatic Stress Disorder
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the completion of enrollment in its ongoing Phase 2 exploratory...
Jun 16, 2020 08:37 am ET
Aptinyx to Present at Upcoming Virtual Investor Conferences
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will be presenting at the following...
May 14, 2020 04:03 pm ET
Aptinyx Reports First Quarter 2020 Financial Results and Highlights
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the first quarter of 2020 and highlighted...
Apr 30, 2020 08:47 am ET
Aptinyx to Report First Quarter Financial Results on Thursday, May 14, 2020
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on...
Mar 30, 2020 04:01 pm ET
Aptinyx Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the fourth quarter and full year 2019 and...
Mar 18, 2020 04:01 pm ET
Aptinyx to Report Fourth Quarter and Full Year 2019 Financial Results on Monday, March 30, 2020
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on...
Feb 19, 2020 08:37 am ET
Aptinyx to Present at Upcoming Investor Conferences
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will be presenting at the following...
Jan 30, 2020 07:07 am ET
Aptinyx Announces Publication of Data in Movement Disorders Demonstrating Reversal of Cognitive Deficits with NYX-458 in Primate Model of Parkinson’s Disease
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced a publication in Movement Disorders detailing data on its novel...
Jan 14, 2020 04:01 pm ET
Aptinyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option
Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the closing of its public offering of 11,691,666 shares of its...
Jan 10, 2020 09:00 am ET
Aptinyx Announces Pricing of Public Offering of Common Stock
Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the pricing of its public offering of 10,166,666 shares of its...
Jan 09, 2020 04:08 pm ET
Aptinyx Announces Proposed Public Offering of Common Stock
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it intends to offer and sell shares of its common stock in an...
Dec 12, 2019 07:07 am ET
Aptinyx to Present at 38th Annual J.P. Morgan Healthcare Conference
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., president and CEO, will present at the...
Dec 09, 2019 04:05 pm ET
Aptinyx to Present Preclinical Data Exhibiting Effects of NYX-783 in Models of PTSD and Alcohol Use Disorder at the American College of Neuropsychopharmacology’s Annual Meeting
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced a presentation highlighting preclinical data on its novel NMDA...
Dec 05, 2019 06:58 am ET
Aptinyx Initiates Phase 2 Study of NYX-458 in Patients with Mild Cognitive Impairment Associated with Parkinson’s Disease
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the initiation of a Phase 2 clinical study of its novel NMDA...
Nov 14, 2019 07:57 am ET
Aptinyx to Present at Upcoming Investor Conferences
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will be presenting at the following...
Nov 12, 2019 04:01 pm ET
Aptinyx Reports Third Quarter 2019 Financial Results and Highlights
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the third quarter of 2019 and highlighted...
Nov 12, 2019 07:27 am ET
Aptinyx Initiates Two Phase 2 Studies of NYX-2925 in Patients with Chronic Centralized Pain Conditions
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the initiation of two Phase 2 studies evaluating NYX-2925 for the...
Nov 11, 2019 08:29 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aptinyx Inc. - APTX
Pomerantz LLP is investigating claims on behalf of investors of  Aptinyx Inc. (“Aptinyx” or the “Company”) (NASDAQ: APTX).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
Nov 05, 2019 08:07 am ET
Aptinyx to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on...
Oct 29, 2019 01:42 pm ET
EQUITY ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Aptinyx Inc.
Levi & Korsinsky reminds investors that it has commenced an investigation of Aptinyx Inc. (“Aptinyx” or “the Company”) (NASDAQ: APTX) concerning possible violations of federal securities laws. Aptinyx completed its initial public offering (“IPO”)...
Oct 29, 2019 01:07 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aptinyx Inc. - APTX
Pomerantz LLP is investigating claims on behalf of investors of  Aptinyx Inc. (“Aptinyx” or the “Company”) (NASDAQ: APTX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
Oct 28, 2019 06:27 pm ET
Kaskela Law LLC Announces Investigation of Aptinyx Inc. (APTX) on Behalf of Investors
Kaskela Law LLC is investigating Aptinyx Inc. (“Aptinyx” or the “Company”) (Nasdaq: APTX) on behalf of the Company’s investors.  Aptinyx investors are encouraged to contact Kaskela Law LLC at (888) 715–1740, or online at...
Oct 28, 2019 07:57 am ET
Aptinyx Announces Results of Phase 2 Fibromyalgia Study of NYX-2925 Have Been Selected for Late-Breaking Presentation at the American College of Rheumatology Annual Meeting
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the results of a Phase 2 study of NYX-2925 in patients with...
Oct 15, 2019 08:46 am ET
Aptinyx to Present Preclinical Data on Three Clinical-Stage NMDA Receptor Modulators at the 49th Annual Meeting of the Society for Neuroscience
Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced five upcoming poster presentations at the 49th Annual Meeting of...
Oct 08, 2019 09:00 pm ET
Aptinyx (APTX) Alert: Johnson Fistel Launches Investigation into Aptinyx Inc.; Investors Suffering Losses Encouraged to Contact Firm
SAN DIEGO, Oct. 8, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Aptinyx Inc. (NASDAQ: APTX) ("Aptinyx") for violations of federal securities laws.
Oct 03, 2019 09:09 pm ET
Bragar Eagel & Squire, P.C. is Investigating Aptinyx, Inc. (NYSE: APTX) on Behalf of Aptinyx Stockholders and Encourages Aptinyx Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against Aptinyx, Inc. (NYSE: APTX) on behalf of Aptinyx stockholders. Our investigation concerns whether Aptinyx has violated the federal securities laws and/or engaged in other unlawful business practices.
Oct 02, 2019 06:59 pm ET
Sep 30, 2019 07:03 am ET
Aptinyx to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Ashish Khanna, chief financial officer and chief business...
Sep 26, 2019 08:07 am ET
Three Recent Preclinical Publications Highlight NMDA Receptor Activation Facilitated by Aptinyx’s NYX-2925
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that preclinical data from the company’s novel NMDA receptor...
Sep 23, 2019 05:27 pm ET
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aptinyx Inc. (“Aptinyx” or “the Company”) (NASDAQ: APTX) for violations of securities laws. If you are a...
Sep 16, 2019 05:06 pm ET
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aptinyx Inc. (“Aptinyx” or “the Company”) (NASDAQ:
Sep 04, 2019 09:21 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aptinyx Inc. (“Aptinyx” or “the Company”) (NASDAQ:
Sep 04, 2019 07:27 am ET
Former Principal Deputy Commissioner of FDA, Dr. Rachel Sherman, Joins Aptinyx Board of Directors
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the appointment of Rachel Sherman, M.D., M.P.H., former principal...
Aug 21, 2019 08:33 am ET
Aptinyx Presents Data Demonstrating Positive Activity of NYX-458 on Cognitive Performance and Biomarkers in a Preclinical Model of Head Injury
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the presentation of preclinical data on its novel NMDA receptor...
Aug 12, 2019 06:33 am ET
Aptinyx Reports Second Quarter 2019 Financial Results and Highlights
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the second quarter of 2019 and recent...
Aug 06, 2019 08:33 am ET
Aptinyx to Present at the 2019 Wedbush PacGrow Healthcare Conference
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., president and chief executive officer,...
Aug 05, 2019 08:03 am ET
Aptinyx to Report Second Quarter 2019 Financial Results on Monday, August 12, 2019
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on...
Jul 12, 2019 08:30 am ET
Aptinyx Salutes Retiring Chief Scientific Officer and NMDA Receptor Drug Discovery Pioneer, Joseph Moskal
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Joseph Moskal, Ph.D., the company’s chief scientific officer,...
Jun 26, 2019 08:03 am ET
Aptinyx Presents Preclinical Data Demonstrating Robust Activity of NYX-783 on Alcohol-Seeking Behavior and Relapse-Like Behavior in Multiple Models of Alcohol Use Disorder
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the presentation of preclinical data on its novel NMDA receptor...
Jun 18, 2019 08:27 am ET
Aptinyx to Present at the 2019 BMO Prescription for Success Healthcare Conference
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Ashish Khanna, chief financial officer and chief business...
Jun 10, 2019 07:23 am ET
Aptinyx Reports Positive Top-line Data from Phase 2 Study of NYX-2925 in Patients with Fibromyalgia, Demonstrating Significant Effects on Both Biomarkers and Patient-Reported Pain
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced positive top-line results from a 23-patient, single-blind,...
May 14, 2019 06:27 am ET
Aptinyx Reports First Quarter 2019 Financial Results and Provides Corporate Update
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the first quarter of 2019 and announced recent...
May 07, 2019 07:23 am ET
Aptinyx Appoints Henry Gosebruch to Its Board of Directors
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the election of Henry O. Gosebruch to its board of directors,...
May 06, 2019 07:27 am ET
Aptinyx to Report First Quarter 2019 Financial Results on Tuesday, May 14, 2019
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on...
Apr 30, 2019 07:27 am ET
Aptinyx Reports Positive Data from Phase 1 Study of Novel NMDA Receptor Modulator, NYX-458, in Healthy Volunteers
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported positive results from a Phase 1 study of its novel NMDA receptor...
Apr 18, 2019 07:27 am ET
Robust Analgesic Activity of Aptinyx’s NYX-2925 in Advanced DPN Patients Revealed Through Further Analysis of Data from Phase 2 Study
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today highlighted detailed analysis of the recently completed Phase 2 study of its...
Apr 09, 2019 07:10 am ET
Market Trends Toward New Normal in Aclaris Therapeutics, Wingstop, South Jersey Industries, LiveRamp, Garrison Capital, and Aptinyx — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Aclaris Therapeutics, Inc. (NASDAQ:ACRS), Wingstop Inc. (NASDAQ:WING),...
Apr 04, 2019 08:00 am ET
Aptinyx to Present at 18th Annual Needham Healthcare Conference
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., president and CEO, will present at the...
Apr 03, 2019 07:27 am ET
Data in Parkinson’s Disease Model in Non-human Primates Demonstrate Reversal of Cognitive Deficits with Novel NMDA Receptor Modulator, NYX-458
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced positive preclinical data on its novel NMDA receptor modulator,...
Mar 28, 2019 07:07 am ET
Aptinyx to Present Detailed Results from Phase 2 Painful DPN Study of NYX-2925 at American Pain Society Scientific Meeting
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced an upcoming poster presentation highlighting the detailed results...
Mar 22, 2019 07:27 am ET
Aptinyx to Present Preclinical Data on NYX-458 at the AD/PD 14th International Conference on Alzheimer’s & Parkinson’s Diseases
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced upcoming presentations highlighting preclinical data on its novel...
Mar 21, 2019 07:07 am ET
Aptinyx Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline and Business Progress
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the fourth quarter and full year 2018 and...
Mar 14, 2019 08:00 am ET
Aptinyx to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, March 21, 2019
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on...
Mar 06, 2019 08:00 am ET
Aptinyx to Present at Cowen and Company 39th Annual Health Care Conference
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., president and CEO, will present at the...
Feb 22, 2019 08:00 am ET
Aptinyx to Present at 8th Annual SVB Leerink Global Healthcare Conference
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., president and CEO, will participate in...
Feb 19, 2019 07:27 am ET
Aptinyx Initiates Phase 2 Study to Evaluate Safety and Efficacy of NYX-783 in Patients with Post-Traumatic Stress Disorder
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it has dosed the first patient in a Phase 2 study of NYX-783...
Jan 16, 2019 07:27 am ET
Aptinyx Reports Top-line Results from Phase 2 Clinical Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced top-line results from a Phase 2 clinical study of NYX-2925 in...
Jan 02, 2019 08:07 am ET
Aptinyx to Present at 37th Annual J.P. Morgan Healthcare Conference
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., president and CEO, will present at the...
Dec 11, 2018 08:27 am ET
Aptinyx to Present Preclinical Data on NMDA Receptor Modulator NYX-2925 at the American College of Neuropsychopharmacology’s Annual Meeting
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced two upcoming poster presentations highlighting preclinical data on...
Dec 05, 2018 08:07 am ET
Aptinyx to Present at BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., president and CEO, will participate in...
Dec 03, 2018 07:27 am ET
Aptinyx Reports Positive Data from Interim Analysis of Exploratory Study of NYX-2925 in Subjects with Fibromyalgia
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced positive results from an interim analysis of an exploratory study...
Nov 21, 2018 07:25 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Atlantic American, Titan Medical, Adial Pharmaceuticals, Aptinyx, Sotherly Hotels, and Titan Pharmaceuticals — New Research Emphasiz
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Atlantic American Corporation (NASDAQ:AAME), Titan Medical Inc....
Nov 13, 2018 07:27 am ET
Aptinyx Reports Third Quarter 2018 Financial Results and Business Highlights
Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results and business highlights for the third quarter ended...
Nov 12, 2018 07:07 am ET
Aptinyx Exploratory Clinical Studies Provide First Evidence that NYX-2925 Elicits Rapid, Persistent, NMDAr-Mediated Pharmacodynamic Activity in Humans
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that exploratory clinical studies of its novel NMDA receptor...
Nov 01, 2018 07:27 am ET
Aptinyx Completes Enrollment in Phase 2 Study of NYX-2925 for Painful Diabetic Peripheral Neuropathy
Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced enrollment completion for the company’s Phase 2 study of NYX-2925...
Oct 29, 2018 08:07 am ET
Aptinyx to Present Preclinical Data on Novel NMDA Receptor Modulators for Pain and Cognition at the 48th Annual Meeting of the Society for Neuroscience
Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced four upcoming poster presentations highlighting preclinical data on...
Sep 25, 2018 04:01 pm ET
Aptinyx to Present at Cantor Fitzgerald Global Healthcare Conference
Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., president and CEO, will present at the Cantor...
Sep 14, 2018 08:07 am ET
Aptinyx Presents Preclinical Data on NMDA Receptor Modulator NYX-2925 at the International Association for the Study of Pain’s 17th World Congress on Pain
Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the presentation of two posters highlighting preclinical data on...
Aug 21, 2018 06:35 am ET
Aptinyx Presents Preclinical Data from Fast-Track Designated PTSD Program at Military Health System Research Symposium
Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced a poster presentation at the Military Health System Research...
Aug 14, 2018 06:27 am ET
Aptinyx Reports Second Quarter 2018 Financial and Business Results
Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results and business highlights for the second quarter...
Aug 02, 2018 08:00 am ET
Aptinyx Initiates Phase 1 Study of NYX-458
Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced initiation of Phase 1 clinical development of NYX-458, its third...
Jun 25, 2018 05:18 pm ET
Aptinyx Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
EVANSTON, Ill., June 25, 2018 /PRNewswire/ -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders, today announced the closing of its initial public offering of 7,359,998 shares of common stock at a public offering price of $16.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 959,999 additional shares. The gross proceeds from the offering are expected to be $117.8 mil
Jun 20, 2018 08:41 pm ET
Aptinyx Announces Pricing of Initial Public Offering
EVANSTON, Ill., June 20, 2018 /PRNewswire/ -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced the pricing of its initial public offering of 6,399,999 shares of its common stock at a public offering price of $16.00 per share. All of the shares are being offered by Aptinyx. In addition, Aptinyx has granted the underwriters a 30-day option to purchase 959,999 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.